Global Human Vaccine Adjuvants Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
- Published Date: 2021-03-14
- Report ID: 65794
- Pages: 103
-
Format:
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Human Vaccine Adjuvants market in this environment.
In terms of revenue, this research report indicated that the global Human Vaccine Adjuvants market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Human Vaccine Adjuvants industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The GSK aims at producing XX K Units Human Vaccine Adjuvants in 2020, with XX % production to take place in global market, CSL Limited accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Human Vaccine Adjuvants Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Human Vaccine Adjuvants Market
GSK
CSL Limited
Brenntag Biosector
SEPPIC
SPI Pharma
Novavax
Avanti Polar Lipids
Aphios
...
Major Type of Human Vaccine Adjuvants Covered in Prudent Markets report:
Research Applications
Commercial Applications
Application Segments Covered in Prudent Markets Market
Oral
Subcutaneous
Intramuscular
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Human Vaccine Adjuvants Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Research Applications -Product Introduction and Major Manufacturers
1.1.2 Commercial Applications -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Human Vaccine Adjuvants Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis
3.1 China Human Vaccine Adjuvants Market
3.1.1 Top Companies leading Human Vaccine Adjuvants Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Human Vaccine Adjuvants Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)
3.2 EU Human Vaccine Adjuvants Market
3.2.1 Top Companies leading Human Vaccine Adjuvants Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Human Vaccine Adjuvants Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)
3.3 USA Human Vaccine Adjuvants Market
3.3.1 Top Companies leading Human Vaccine Adjuvants Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Human Vaccine Adjuvants Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)
3.4 Japan Human Vaccine Adjuvants Market
3.4.1 Top Companies leading Human Vaccine Adjuvants Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Human Vaccine Adjuvants Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)
3.5 India Human Vaccine Adjuvants Market
3.5.1 Top Companies leading Human Vaccine Adjuvants Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Human Vaccine Adjuvants Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)
3.6 Southeast Asia Human Vaccine Adjuvants Market
3.6.1 Top Companies leading Human Vaccine Adjuvants Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Human Vaccine Adjuvants Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Human Vaccine Adjuvants Market
3.7.1 Top Companies leading Human Vaccine Adjuvants Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Human Vaccine Adjuvants Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)
4.1 Human Vaccine Adjuvants Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Human Vaccine Adjuvants Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)
5.1 Global Human Vaccine Adjuvants Sales and Growth Rate (2021-2027)
5.2 Global Human Vaccine Adjuvants Sales Value and Growth Rate (2021-2027)
6 Human Vaccine Adjuvants Competitive Analysis
6.1 GSK
6.1.1 GSK Company Profiles
6.1.2 GSK Product Introduction
6.1.3 GSK Human Vaccine Adjuvants Production, Revenue (2016-2021)
6.1.4 SWOT Analysis
6.2 CSL Limited
6.2.1 CSL Limited Company Profiles
6.2.2 CSL Limited Product Introduction
6.2.3 CSL Limited Human Vaccine Adjuvants Production, Revenue (2016-2021)
6.2.4 SWOT Analysis
6.3 Brenntag Biosector
6.3.1 Brenntag Biosector Company Profiles
6.3.2 Brenntag Biosector Product Introduction
6.3.3 Brenntag Biosector Human Vaccine Adjuvants Production, Revenue (2016-2021)
6.3.4 SWOT Analysis
6.4 SEPPIC
6.4.1 SEPPIC Company Profiles
6.4.2 SEPPIC Product Introduction
6.4.3 SEPPIC Human Vaccine Adjuvants Production, Revenue (2016-2021)
6.4.4 SWOT Analysis
6.5 SPI Pharma
6.5.1 SPI Pharma Company Profiles
6.5.2 SPI Pharma Product Introduction
6.5.3 SPI Pharma Human Vaccine Adjuvants Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6 Novavax
6.6.1 Novavax Company Profiles
6.6.2 Novavax Product Introduction
6.6.3 Novavax Human Vaccine Adjuvants Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 Avanti Polar Lipids
6.7.1 Avanti Polar Lipids Company Profiles
6.7.2 Avanti Polar Lipids Product Introduction
6.7.3 Avanti Polar Lipids Human Vaccine Adjuvants Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 Aphios
6.8.1 Aphios Company Profiles
6.8.2 Aphios Product Introduction
6.8.3 Aphios Human Vaccine Adjuvants Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
7 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
